FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Miles Prince

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Madeleine Duvic; David P Fivenson; Ann G Martin; Elise A Olsen; H Miles Prince
Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma.
Amit Khot; H Miles Prince; John F Seymour; Kerrie Stokes; Dominic Wall; Kate Burbury; Michael Dickinson; Shaun Fleming; Peter Gambell; Simon Harrison; David Ritchie
A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation.
Madeleine Duvic; Maria Grazia Bernengo; Céleste Lebbé; Miriam Marshood; Pablo Ortiz Romero; Nicolas Poulalhon; Chalid Assaf; Jürgen C Becker; Reinhard Dummer; Margaret Squier; Feng Tai; Denise Williams; H Miles Prince
Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Miles Prince (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Madeleine Duvic; David P Fivenson; Ann G Martin; Elise A Olsen; H Miles Prince
Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma.
Leukemia & lymphoma 2013;54(3):514-9.
2013: Amit Khot; H Miles Prince; John F Seymour; Kerrie Stokes; Dominic Wall; Kate Burbury; Michael Dickinson; Shaun Fleming; Peter Gambell; Simon Harrison; David Ritchie
A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation.
Clinical lymphoma, myeloma & leukemia 2013;13(1):42-7.
2013: Madeleine Duvic; Maria Grazia Bernengo; Céleste Lebbé; Miriam Marshood; Pablo Ortiz Romero; Nicolas Poulalhon; Chalid Assaf; Jürgen C Becker; Reinhard Dummer; Margaret Squier; Feng Tai; Denise Williams; H Miles Prince
Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
European journal of cancer (Oxford, England : 1990) 2013;49(2):386-94.
2013: H Miles Prince; David P Fivenson; Ann G Martin; Elise A Olsen; Madeleine Duvic
Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome.
Leukemia & lymphoma 2013;54(1):69-75.
2012: Shane A Gangatharan; Dennis A Carney; E Henry Januszewicz; H Miles Prince; David S Ritchie; Max M Wolf; Simon J Harrison
Emergence of central nervous system myeloma in the era of novel agents.
Hematological oncology 2012;30(4):170-4.
2012: Piers Blombery; Stephen Lade; Stephen Q Wong; H Miles Prince
Erdheim-Chester disease harboring the BRAF V600E mutation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(32):e331-2.
2012: H Miles Prince; Wolfram Sterry; Chalid Assaf; Madeleine Duvic; Ann Martin; David J Straus
Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placebo.
Journal of the American Academy of Dermatology 2012;67(5):867-75.
2012: Simon J Harrison; Ricky Johnstone; Becki Lee; Richard L Piekarz; Maria E Araujo; Susan E Bates; Mark J Bishton; Yun Dai; Steven Grant; H Miles Prince
A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).
Epigenomics 2012;4(5):571-89.
2012: H Miles Prince
Pioneering studies of histone deacetylase inhibitors in myeloma: signals of activity set the stage for combination therapy trials.
Leukemia & lymphoma 2012;53(9):1658-9.
2012: H Miles Prince; Michael Dickinson
Romidepsin for cutaneous T-cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(13):3509-15.
2012: Anas Younes; Pier Luigi Zinzani; Dina Ben-Yehuda; Jennifer Gallagher; Simon J Harrison; Patrick Johnston; Mark Kirschbaum; Christophe Le Corre; Tee-Chuan Ong; H Miles Prince; Angela Shen; Anna Sureda; Andreas Engert
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(18):2197-203.
2012: Peter Mollee; John Moore; Sanjoy Paul; H Miles Prince; Jill Tate; Campbell Tiley; Paul Cannell; Ilona Cunningham; Steve Gibbons; Helen Mar Fan; Devinder S Gill
A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis.
British journal of haematology 2012;157(6):766-9.
2012: Peter Gambell; Simon Harrison; Kirsten Herbert; Mathias Bressel; Michael Dickinson; Kerrie Stokes; Dominic Wall; H Miles Prince
Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield: an analysis of more than 1,000 collections.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012;18(5):763-72.
2012: Kim O Taylor; Howard R Webster; H Miles Prince
Anaplastic large cell lymphoma and breast implants: five Australian cases.
Plastic and reconstructive surgery 2012;129(4):610e-7e.
2012: H Miles Prince
Fludarabine and a histone deacetylase inhibitor - strange bedfellows.
Leukemia research 2012;36(4):385-6.
2012: Bertrand Coiffier; Francine M Foss; Matthew Greenwood; Barbara Balser; John Balser; Peter Borchmann; Dolores Caballero; Susan Carroll; Franck Morschhauser; Jean Nichols; Swaminathan Padmanabhan; Lauren Pinter-Brown; H Miles Prince; Barbara Pro; Andrei Shustov; Lubomir Sokol; Martin Wilhelm; Steven Horwitz
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(6):631-6.
2012: Sarah Shen; Lei Mee Yap; Tim O'Brien; H Miles Prince; Christopher McCormack
The use of methotrexate in dermatology: a review.
The Australasian journal of dermatology 2012;53(1):1-18.
2012: Shuo Li; Bruce E Loveland; Magdalena Plebanski; H Miles Prince; Stuart Roberts; Rosemary L Sparrow; Tim Spelman; Lorena Brown; Maelenn Gouillou; Derek Hart; David Jackson; Philippe Latour; Eric J Gowans
Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in hepatitis C virus infected individuals.
PloS one 2012;7(8):e39368.
2011: Senthil Lingaratnam; Linda Mileshkin; Mary O'Reilly; H Miles Prince; John F Seymour; Monica A Slavin; Jeff Szer; Craig A Bennett; Andrew Dalton; Sue W Kirsa; Bogda Koczwara; Leon J Worth; Karin Thursky
A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment.
Australian health review : a publication of the Australian Hospital Association 2011;35(4):491-500.
2011: Werner Kempf; Youn H Kim; Robert Knobler; Elise Olsen; Pablo L Ortiz-Romero; Sonja Ostheeren-Michaelis; Katrin Pfaltz; Nicola Pimpinelli; H Miles Prince; Annamari Ranki; José A Sanches; Maarten H Vermeer; Sean Whittaker; Martine Bagot; Emilio Berti; Lorenzo Cerroni; Antonio Cozzio; Brigitte Dreno; Reinhard Dummer; Madeleine Duvic; Teresa Estrach; Joan Guitart; Emmilia Hodak; Steve Horwitz; Gary Wood; Rein Willemze
EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Blood 2011;118(15):4024-35.
2011: Piers Blombery; Jo Main; H Miles Prince; Erica M Wood; Leon J Worth; Melissa Yang; David A Westerman
Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications.
Annals of hematology 2011;90(10):1167-72.
2011: Shane A Gangatharan; Melita K Kenealy; H Miles Prince; Lynda J Campbell; Dennis A Carney; John F Seymour
Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
European journal of haematology 2011;87(2):186-8.
2011: Kate L Burbury; Mark J Bishton; Ricky W Johnstone; Michael J Dickinson; Jeffrey Szer; H Miles Prince
MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi).
Annals of hematology 2011;90(7):847-9.
2011: Richard L Piekarz; Robin Frye; H Miles Prince; Mark H Kirschbaum; Jasmine Zain; Steven Allen; Elaine S Jaffe; Alexander Ling; Maria Turner; Cody J Peer; William D Figg; Seth M Steinberg; Sonali Smith; David Joske; Ian Lewis; Laura Hutchins; Michael Craig; Antonio Tito Fojo; John J Wright; Susan E Bates
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
Blood 2011;117(22):5827-34.
2011: Hang Quach; H Miles Prince; Andrew Spencer
Managing multiple myeloma in the elderly: are we making progress?
Expert review of hematology 2011;4(3):301-15.
2011: P A Thompson; H Miles Prince; John F Seymour; D Ritchie; K Stokes; K Burbury; Max Wolf; Stefan Peinert; T Joyce; S J Harrison
Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma.
Bone marrow transplantation 2011;46(5):764-5.
2011: Melissa G Lechner; Stephen Lade; Daniel J Liebertz; H Miles Prince; Garry S Brody; Howard R Webster; Alan L Epstein
Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity.
Cancer 2011;117(7):1478-89.
2011: Mark J Bishton; Simon J Harrison; Benjamin P Martin; Nicole McLaughlin; Chloé James; Emma C Josefsson; Katya J Henley; Benjamin T Kile; H Miles Prince; Ricky Johnstone
Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia.
Blood 2011;117(13):3658-68.
2011: Rebecca A Howman; H Miles Prince
New drug therapies in peripheral T-cell lymphoma.
Expert review of anticancer therapy 2011;11(3):457-72.
2011: Piers Blombery; H Miles Prince; Michele Levinson; Stephen Pianko; Ellen Maxwell; Prithi Bhathal
Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e110-2.
2011: Andy K Hsu; Hang Quach; Tsin Tai; H Miles Prince; Simon J Harrison; Joseph A Trapani; Mark J Smyth; Paul Neeson; David S Ritchie
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.
Blood 2011;117(5):1605-13.
2011: Hollie J Pegram; David S Ritchie; Mark J Smyth; Andres Wiernik; H Miles Prince; Phillip K Darcy; Michael H Kershaw
Alloreactive natural killer cells in hematopoietic stem cell transplantation.
Leukemia research 2011;35(1):14-21.
2010: Michael Dickinson; Ricky W Johnstone; H Miles Prince
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.
Investigational new drugs 2010;28 Suppl 1():S3-20.
2010: H Miles Prince
The deacetylase inhibitors--here to stay!
Investigational new drugs 2010;28 Suppl 1():S1-2.
2010: D A Carney; David Westerman; Constantine S Tam; A Milner; H Miles Prince; M Kenealy; Max Wolf; E Henry Januszewicz; David Ritchie; N Came; John F Seymour
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
Leukemia 2010;24(12):2056-62.
2010: Stefan Peinert; Constantine S Tam; H Miles Prince; John Scarlett; Max M Wolf; E Henry Januszewicz; David Westerman; John F Seymour
Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia.
Leukemia & lymphoma 2010;51(12):2188-97.
2010: Philip A Thompson; Stephen Lade; Howard Webster; Gail Ryan; H Miles Prince
Effusion-associated anaplastic large cell lymphoma of the breast: time for it to be defined as a distinct clinico-pathological entity.
Haematologica 2010;95(11):1977-9.
2010: Eric J Gowans; Stuart Roberts; Kathryn Jones; Irene Dinatale; Philippe A Latour; Brendan Chua; Emily M Y Eriksson; Ruth Chin; Shuo Li; Dominic M Wall; Rosemary L Sparrow; Jude Moloney; Maureen Loudovaris; Rosemary Ffrench; H Miles Prince; Derek Hart; Weng Zeng; Joseph Torresi; Lorena E Brown; David C Jackson
A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals.
Journal of hepatology 2010;53(4):599-607.
2010: Michael Dickinson; Rosemary Hoyt; Andrew W Roberts; Andrew Grigg; John F Seymour; H Miles Prince; Jeff Szer; David Ritchie
Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy.
British journal of haematology 2010;150(1):39-45.
2010: Mun Sem Liew; Andrea M Chan; Stuart Galloway; Giulio Comin; Brendan Flaim; H Miles Prince; Hang Quach
Extra-nasal NK/T cell lymphoma masquerading as renal infarction.
Leukemia & lymphoma 2010;51(6):1139-41.
2010: Stefan Peinert; H Miles Prince; P M Guru; Michael H Kershaw; Mark J Smyth; Joseph A Trapani; P Gambell; S Harrison; Andrew M Scott; F E Smyth; Phillip K Darcy; Kellie M Tainton; P Neeson; David S Ritchie; D Hönemann
Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.
Gene therapy 2010;17(5):678-86.
2010: H Miles Prince; Madeleine Duvic; Ann Martin; Wolfram Sterry; Chalid Assaf; Yijun Sun; David J Straus; Mark Acosta; andres negro vilar
Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(11):1870-7.
2010: Shriram Vaidia Nath; Modisha Peiris; Mark J Bishton; Ellen Maxwell; H Miles Prince
Light chain deposition disease presenting as massive hepatomegaly.
Pathology 2010;42(3):307-10.
2010: Andrew P Grigg; Janey Stone; Alvin D Milner; Anthony P Schwarer; Max Wolf; H Miles Prince; John Seymour; Devinder Gill; David Ellis; John Bashford
Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma.
Leukemia & lymphoma 2010;51(4):641-9.
2010: Alastair B Law; Gail Ryan; Stephen Lade; H Miles Prince
Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient.
International journal of hematology 2010;91(2):347-8; author reply 349.
2010: A C Chan; P Neeson; E Leeansyah; K Tainton; H Quach; H Miles Prince; D I Godfrey; D Ritchie; Stuart P Berzins
Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients.
Leukemia 2010;24(3):592-600.
2010: S Gill; D Carney; David Ritchie; Max Wolf; David Westerman; H Miles Prince; H Januszewicz; John F Seymour
The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(2):331-4.
2010: Kirsten E Herbert; H Miles Prince; David S Ritchie; John F Seymour
The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution.
Expert opinion on biological therapy 2010;10(1):113-25.
2010: H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H Miles Prince
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.
Leukemia 2010;24(1):22-32.
2009: H Miles Prince; Sean Whittaker; Richard T Hoppe
How I treat mycosis fungoides and Sézary syndrome.
Blood 2009;114(20):4337-53.
2009: Richard L Piekarz; Robin Frye; Maria Turner; John J Wright; Steven Allen; Mark H Kirschbaum; Jasmine Zain; H Miles Prince; John P Leonard; Larisa J Geskin; Craig Reeder; David Joske; William D Figg; Erin R Gardner; Seth M Steinberg; Elaine S Jaffe; Maryalice Stetler-Stevenson; Stephen Lade; A Tito Fojo; Susan E Bates
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(32):5410-7.
2009: Stefan Peinert; Michael H Kershaw; H Miles Prince
Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
Immunotherapy 2009;1(6):905-12.
2009: David Ritchie; Richard L Piekarz; Piers Blombery; Laszlo J Karai; Stefania Pittaluga; Elaine S Jaffe; Mark Raffeld; John E Janik; H Miles Prince; Susan E Bates
Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report.
Haematologica 2009;94(11):1618-22.
2009: Saar Gill; Kirsten E Herbert; H Miles Prince; Max M Wolf; Andrew Wirth; Gail Ryan; Dennis A Carney; David S Ritchie; John M Davies; John F Seymour
Mantle cell lymphoma with central nervous system involvement: frequency and clinical features.
British journal of haematology 2009;147(1):83-8.
2009: Stefan Peinert; Dennis Carney; H Miles Prince; E Henry Januszewicz; John F Seymour
Fludarabine combinations for patients with advanced marginal zone lymphomas--best treatment option or too toxic?
British journal of haematology 2009;146(6):685-6.
2009: Violet Kieu; Timothy O'Brien; Lee Mei Yap; Christopher Baker; Peter Foley; Graham Mason; H Miles Prince; Christopher McCormack
Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab.
The Australasian journal of dermatology 2009;50(3):202-6.
2009: Paul J Kim; Rodney J Hicks; Andrew Wirth; Gail Ryan; John F Seymour; H Miles Prince; Michael Mac Manus
Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma.
International journal of radiation oncology, biology, physics 2009;74(3):740-6.
2009: H Miles Prince; Mark J Bishton; Simon J Harrison
Clinical studies of histone deacetylase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):3958-69.
2009: H Miles Prince; Mark J Bishton; Ricky Johnstone
Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors.
Future oncology (London, England) 2009;5(5):601-12.
2009: H Miles Prince; Dirk Hönemann; Andrew Spencer; David A Rizzieri; Edward A Stadtmauer; Andrew W Roberts; Nizar Bahlis; Guido Tricot; Bill Bell; Douglas J Demarini; A Benjamin Suttle; Katherine L Baker; Lini N Pandite
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).
Blood 2009;113(19):4819-20.
2009: Michelle Rodrigues; Christopher McCormack; Lee Mei Yap; H Miles Prince; Hugh Roberts; Richard Williams; Peter Foley
Successful treatment of lymphomatoid papulosis with photodynamic therapy.
The Australasian journal of dermatology 2009;50(2):129-32.
2009: M Dickinson; H Miles Prince; S Kirsa; A Zannettino; Simon Gibbs; Linda Mileshkin; J O'Grady; John F Seymour; J Szer; N Horvath; D E Joshua
Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment.
Internal medicine journal 2009;39(5):304-16.
2009: Andrew Spencer; H Miles Prince; Andrew W Roberts; Ian W Prosser; Kenneth F Bradstock; Luke Coyle; Devinder S Gill; Noemi Horvath; John Reynolds; Nola Kennedy
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(11):1788-93.
2009: Stefan Peinert; Sarah Kamel; John F Seymour; H Miles Prince
Intralesional rituximab for the treatment of localised palatal relapse of follicular lymphoma.
Leukemia & lymphoma 2009;50(2):303-5.
2009: K E Herbert; S Morgan; H Miles Prince; David Westerman; Max M Wolf; D A Carney; K Yuen; Juliana Di Iulio; John F Seymour
Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator.
Leukemia 2009;23(2):305-12.
2009: Mark A Dawson; Stephen S Opat; Yamna Taouk; Mark Donovan; Michele Zammit; Katherine Monaghan; Noemi Horvath; Andrew W Roberts; H Miles Prince; Mark Hertzberg; Catriona A McLean; Andrew Spencer
Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(2):714-22.
2009: Joseph R Mikhael; Andrew R Belch; H Miles Prince; Maria Nambo Lucio; Angelo Maiolino; Alessandro Corso; Maria Teresa Petrucci; Pellegrino Musto; Mieczyslaw Komarnicki; A Keith Stewart
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
British journal of haematology 2009;144(2):169-75.
2008: Suzanne O Arulogun; H Miles Prince; Jonathan Ng; Stephen Lade; Gail F Ryan; Odette Blewitt; Christopher McCormack
Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation.
Blood 2008;112(8):3082-7.
2008: Suzanne Arulogun; H Miles Prince; Peter Gambell; Stephen Lade; Gail Ryan; Eve Eaton; Christopher McCormack
Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol.
Journal of the American Academy of Dermatology 2008;59(4):589-95.
2008: Mary E D Flowers; Jane F Apperley; Koen van Besien; Ahmet Elmaagacli; Andrew Grigg; Vijay Reddy; Andrea Bacigalupo; Hans-Jochem Kolb; Luis Bouzas; Mauricette Michallet; H Miles Prince; Robert Knobler; Dennis Parenti; Jose Gallo; Hildegard T Greinix
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease.
Blood 2008;112(7):2667-74.
2008: Saar Gill; Steven W Lane; Julie Crawford; Gavin Cull; David Joske; Paula Marlton; Peter N Mollee; H Miles Prince; John F Seymour
Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients.
Annals of hematology 2008;87(9):727-34.
2008: Leigh Ellis; Yan Pan; Gordon K Smyth; Daniel J George; Chris McCormack; Roxanne Williams-Truax; Monica Mita; Joachim Beck; Howard Burris; Gail Ryan; Peter Atadja; Dale Butterfoss; Margaret Dugan; Kenneth Culver; Ricky Johnstone; H Miles Prince
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4500-10.
2008: Jennifer A Westwood; W K Murray; M Trivett; A Shin; P Neeson; D P MacGregor; N M Haynes; Joseph A Trapani; P Mayura-Guru; S Fox; S Peinert; D Honemann; H Miles Prince; D Ritchie; Andrew M Scott; F E Smyth; Mark J Smyth; P K Darcy; Michael H Kershaw
Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice.
Gene therapy 2008;15(14):1056-66.
2008: Saar Gill; Max Wolf; H Miles Prince; H Januszewicz; David Ritchie; Rodney J Hicks; John F Seymour
[18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma.
Clinical lymphoma & myeloma 2008;8(3):159-65.
2008: Stefan Peinert; H Miles Prince; Simon Harrison
The development of novel immunotherapeutic approaches in multiple myeloma.
Leukemia & lymphoma 2008;49(4):652-4.
2008: Walid Rasheed; Mark Bishton; Ricky Johnstone; H Miles Prince
Histone deacetylase inhibitors in lymphoma and solid malignancies.
Expert review of anticancer therapy 2008;8(3):413-32.
2008: H Miles Prince; Mark Bishton; Simon Harrison
The potential of histone deacetylase inhibitors for the treatment of multiple myeloma.
Leukemia & lymphoma 2008;49(3):385-7.
2008: Jayne S Sutherland; Lisa Spyroglou; Jennifer L Muirhead; Tracy S Heng; Adria Prieto-Hinojosa; H Miles Prince; Ann P Chidgey; Anthony P Schwarer; Richard L Boyd
Enhanced immune system regeneration in humans following allogeneic or autologous hemopoietic stem cell transplantation by temporary sex steroid blockade.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(4):1138-49.
2008: H Miles Prince; Dominic M Wall; David Ritchie; Dirk Honemann; Simon Harrrison; Hang Quach; Mick Thompson; Rodney Hicks; Eddie Lau; Jill Davison; Maureen Loudovaris; Jude Moloney; Bruce Loveland; Jacques Bartholeyns; Andrew Katsifis; Linda Mileshkin
In vivo tracking of dendritic cells in patients with multiple myeloma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(2):166-79.
2008: Lei Zhang; David Lebwohl; Eric Masson; Glen Laird; Michael R Cooper; H Miles Prince
Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):332-3; discussion 333-4.
2008: Nadège Bercovici; Nacilla Haicheur; Severine Massicard; Frédérique Vernel-Pauillac; Olivier Adotevi; Didier Landais; Isabelle Gorin; Caroline Robert; H Miles Prince; Jean-Jacques Grob; Marie-Thérèse Leccia; Thierry Lesimple; John Wijdenes; Jacques Bartholeyns; Wolf H Fridman; Margarita Salcedo; Estelle Ferries; Eric Tartour
Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(1):101-12.
2008: J Green; E Upjohn; Christopher McCormack; Jerome B Zeldis; H Miles Prince
Successful treatment of Behçet's disease with lenalidomide.
The British journal of dermatology 2008;158(1):197-8.
2007: Meletios A Dimopoulos; Andrew Spencer; Michael Attal; H Miles Prince; Jean-Luc Harousseau; Anna Dmoszynska; Jesus San Miguel; Andrzej Hellmann; Thierry Facon; Robin Foà; Alessandro Corso; Zvenyslava Masliak; Marta Olesnyckyj; Zhinuan Yu; John Patin; Jerome B Zeldis; Robert D Knight
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
The New England journal of medicine 2007;357(21):2123-32.
2007: Mark Bishton; Melita Kenealy; Ricky Johnstone; Walid Rasheed; H Miles Prince
Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Expert review of anticancer therapy 2007;7(10):1439-49.
2007: Saar Gill; Jeremy Shapiro; David Westerman; H Miles Prince
Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(28):4493-4.
2007: Linda Mileshkin; Dirk Honemann; Peter Gambell; Melanie Trivett; Yoshihiro Hayakawa; Mark Smyth; Victoria Beshay; David Ritchie; Paul Simmons; Alvin D Milner; Jerome B Zeldis; H Miles Prince
Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
Haematologica 2007;92(8):1075-82.
2007: H Miles Prince; Michael Adena; Dell Kingsford Smith; Judy Hertel
Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.
European journal of haematology 2007;79(2):93-9.
2007: Walid K Rasheed; Ricky Johnstone; H Miles Prince
Histone deacetylase inhibitors in cancer therapy.
Expert opinion on investigational drugs 2007;16(5):659-78.
2007: M S Y Goh; C McCormack; Hope V Dinh; B Welsh; P Foley; H Miles Prince
Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients.
The British journal of dermatology 2007;156(5):990-6.
2007: J B Ruddle; H Miles Prince
Denileukin diftitox and vision loss.
Leukemia & lymphoma 2007;48(4):655-6.
2007: H Miles Prince; B Schenkel; Linda Mileshkin
Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.
Leukemia 2007;21(4):818-20; author reply 821.
2007: Ashley Ng; Andrew Wirth; John F Seymour; Michael Lee; Annette Hogg; Henry Januszewicz; Max Wolf; H Miles Prince; Michael Mac Manus; Rodney J Hicks
Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure.
Leukemia & lymphoma 2007;48(3):596-600.
2007: E Upjohn; Peter Foley; P Lane; J Magee; H Miles Prince; Christopher McCormack; R Sinclair
Long-term clearance of patch-stage mycosis fungoides with the 308-nm laser.
Clinical and experimental dermatology 2007;32(2):168-71.
2007: Kirsten E Herbert; Carl R Walkley; Ingrid G Winkler; Jean Hendy; Gemma Haines Olsen; Yang-Dar Yuan; Roshantha A S Chandraratna; H Miles Prince; Jean-Pierre Lévesque; Louise E Purton
Granulocyte colony-stimulating factor and an RARalpha specific agonist, VTP195183, synergize to enhance the mobilization of hematopoietic progenitor cells.
Transplantation 2007;83(4):375-84.
2007: David S Ritchie; John F Seymour; Andrew P Grigg; Andrew W Roberts; R Hoyt; S Thompson; Jeff Szer; H Miles Prince
The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
Annals of hematology 2007;86(2):101-5.
2007: David Ritchie; Linda Mileshkin; D Wall; J Bartholeyns; M Thompson; J Coverdale; E Lau; J Wong; P Eu; Rodney J Hicks; H Miles Prince
In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma.
Cancer immunology, immunotherapy : CII 2007;56(2):155-63.
2007: Hang Quach; H Miles Prince; Linda Mileshkin
Treatment strategies in elderly patients with multiple myeloma: current status.
Drugs & aging 2007;24(10):829-50.
2007: Susan K Nilsson; H Miles Prince; D Wall; David N Haylock
Recent Australian experience with hemopoietic stem and progenitor cell expansion.
Cytotherapy 2007;9(3):231-5.
2007: H Miles Prince; Brad Schenkel; Linda Mileshkin
An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma.
Leukemia & lymphoma 2007;48(1):46-55.
2007: Hope V Dinh; Christopher McCormack; Stephen Hall; H Miles Prince
Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases.
Journal of the American Academy of Dermatology 2007;56(1):148-53.
2006: Simon J Harrison; Gordon Cook; Robert J B Nibbs; H Miles Prince
Immunotherapy of multiple myeloma: the start of a long and tortuous journey.
Expert review of anticancer therapy 2006;6(12):1769-85.
2006: Heather Robinson; H Miles Prince; Shakher Ramdave; John F Seymour; Patrick Elliott; Rod Hicks
Preliminary experience of 18F-fluorodeoxyglucose positron emission tomography in Castleman's disease.
Leukemia & lymphoma 2006;47(12):2664-6.
2006: M Kenealy; H Miles Prince
Current status of new drugs for the treatment of patients with multiple myeloma.
Internal medicine journal 2006;36(12):781-9.
2006: Linda Mileshkin; H Miles Prince
The troublesome toxicity of peripheral neuropathy with thalidomide.
Leukemia & lymphoma 2006;47(11):2276-9.
2006: Dirk Hönemann; H Miles Prince
Myeloma, thalidomide and thrombosis.
Leukemia & lymphoma 2006;47(11):2273-5.
2006: Constantine S Tam; John F Seymour; H Miles Prince; Melita Kenealy; Max Wolf; E Henry Januszewicz; David Westerman
Treatment-related myelodysplasia following fludarabine combination chemotherapy.
Haematologica 2006;91(11):1546-50.
2006: Michelle Rodrigues; David Westerman; Stephen Lade; Christopher McCormack; H Miles Prince
Methotrexate-induced lymphoproliferative disorder in a patient with Sézary syndrome.
Leukemia & lymphoma 2006;47(10):2257-9.
2006: Linda Mileshkin; Richard Stark; Bruce Day; John F Seymour; Jerome B Zeldis; H Miles Prince
Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(27):4507-14.
2006: Heather Robinson; Matthew Damasiewicz; Dirk Hönemann; Stephen Lade; Alex Boussioutas; H Miles Prince
Gastric involvement of plasmacytoma associated with t(4:14) and chromosome 13 deletion.
Leukemia & lymphoma 2006;47(9):1973-5.
2006: Steven W Lane; Julie Crawford; Melita Kenealy; Gavin Cull; John F Seymour; H Miles Prince; Paula Marlton; Devinder Gill; Peter Mollee
Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
Leukemia & lymphoma 2006;47(9):1813-7.
2006: Colm Keane; Simon Gibbs; John F Seymour; Anthony K Mills; Karen Grimmett; Rosita Van Kuilenberg; Russell Saal; Devinder Gill; H Miles Prince; Paula Marlton; Peter Mollee
The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization.
Hematological oncology 2006;24(3):159-63.
2006: Mark Polizzotto; Constantine S Tam; Alvin Milner; E Henry Januszewicz; H Miles Prince; David Westerman; Max M Wolf; John F Seymour
The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.
Cancer 2006;107(4):773-80.
2006: Melita K Kenealy; H Miles Prince; Dirk Hönemann
Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma.
Pharmacotherapy 2006;26(8):1205-6; discussion 1206.
2006: Florent Cachin; H Miles Prince; Annette Hogg; Robert E Ware; Rodney J Hicks
Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3026-31.
2006: Rudolf J Schrover; Michael A Adena; Richard De Abreu Lourenco; H Miles Prince; John F Seymour; Michael J Wonder
Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase.
Leukemia & lymphoma 2006;47(6):1069-81.
2006: Constantine S Tam; Max Wolf; H Miles Prince; E Henry Januszewicz; David Westerman; Katherine I Lin; Dennis Carney; John F Seymour
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Cancer 2006;106(11):2412-20.
2006: Heather E Robinson; Ellen L Maxwell; H Miles Prince; Mary A O'Reilly; Andrew Jakobovits
Cefotetan-induced life-threatening haemolysis.
The Medical journal of Australia 2006;184(5):251.
2006: Maher K Gandhi; Eleanore Lambley; Jacqueline M Burrows; Ujjwal Dua; Suzanne Elliott; Peter Shaw; H Miles Prince; Max Wolf; Kerrie Clarke; Craig Underhill; Tony Mills; Peter Mollee; Devinder Gill; Paula Marlton; John F Seymour; Rajiv Khanna
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(2):460-4.
2006: Ashley Ng; Stephen Lade; Timothy Rutherford; Christopher McCormack; H Miles Prince; David Westerman
Primary cutaneous CD4+/CD56+ hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases.
Haematologica 2006;91(1):143-4.
2005: Jennifer A Westwood; Mark J Smyth; Michele W L Teng; Maria Moeller; Joseph A Trapani; Andrew M Scott; Fiona E Smyth; Glenn A Cartwright; Barbara E Power; Dirk Hönemann; H Miles Prince; Phillip K Darcy; Michael H Kershaw
Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(52):19051-6.
2005: Ashley Ng; Leon Worth; Luke F. Chen; John F Seymour; H Miles Prince; Monica Slavin; Karin Thursky
Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
Haematologica 2005;90(12):1672-9.
2005: Simon Gibbs; John O'Grady; John F Seymour; H Miles Prince
Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention.
The Medical journal of Australia 2005;183(10):549-50.
2005: Linda Mileshkin; John F Seymour; Max M Wolf; P Gates; E Henry Januszewicz; P Joyce; H Miles Prince
Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older.
Leukemia & lymphoma 2005;46(11):1575-9.
2005: Kenneth C Anderson; H Miles Prince
Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
Seminars in hematology 2005;42(4 Suppl 4):S1-2.
2005: Constantine S Tam; Max M Wolf; David Westerman; E Henry Januszewicz; H Miles Prince; John F Seymour
Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
Clinical lymphoma & myeloma 2005;6(2):136-9.
2005: Simon Gibbs; David Westerman; Stephen Lade; Christopher McCormack; John F Seymour; H Miles Prince
Early B-cell chronic lymphocytic leukemia presenting as cutaneous lesions with a normal peripheral blood lymphocyte count.
Journal of the American Academy of Dermatology 2005;53(3):535-6.
2005: H Miles Prince; Linda Mileshkin; Andrew Roberts; Vinod Ganju; Craig Underhill; John Catalano; Richard Bell; John F Seymour; David Westerman; Paul J Simmons; Kate Lillie; Alvin D Milner; Juliana Di Iulio; Jerome B Zeldis; Robert Ramsay
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(15):5504-14.
2005: Linda Mileshkin; H Miles Prince
The adverse prognostic impact of advanced age in multiple myeloma.
Leukemia & lymphoma 2005;46(7):951-66.
2005: H Miles Prince; Geoff Regester; Priscilla Gates; Lina Jablonskis; John F Seymour; Kate Lillie; Raelene West; Max Wolf; Henry Januszewicz; David Belford
A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2005;11(7):512-20.
2005: Dirk Hönemann; H Miles Prince; John F Seymour; Max M Wolf; David Westerman; E Henry Januszewicz
A phase II study of liposomal doxorubicin, vincristine and dexamethasone in multiple myeloma.
Leukemia & lymphoma 2005;46(6):945-7.
2005: S Brennand; V R Sutton; J Biagi; J A Trapani; David Westerman; Christopher McCormack; John F Seymour; G Kennedy; H Miles Prince
Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
The British journal of dermatology 2005;152(6):1199-205.
2005: Tara Seshadri; H Miles Prince; David R Bell; Paul B Coughlin; Philip P B James; Gary E Richardson; Boris Chern; Peter Briggs; John Norman; Ian N Olver; Christos Karapetis; John Stewart
The Australian Cancer Anaemia Survey: a snapshot of anaemia in adult patients with cancer.
The Medical journal of Australia 2005;182(9):453-7.
2005: Fiona Chionh; Kirsten E Herbert; John F Seymour; H Miles Prince; Max Wolf; Alan Zimet; Constantine Tam; Glen A Kennedy
Ante-mortem diagnosis of localized invasive esophageal aspergillosis in a patient with acute myeloid leukemia.
Leukemia & lymphoma 2005;46(4):603-5.
2005: J J Biagi; K E Herbert; C Smith; E Abdi; M Leahy; C Falkson; Max Wolf; H Januszewicz; John F Seymour; K Richards; Jane P Matthews; B Dale; H Miles Prince
A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma.
Leukemia & lymphoma 2005;46(2):197-206.
2005: Dirk Hönemann; H Miles Prince; Rodney J Hicks; John F Seymour
Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease: diagnostic dilemmas and management options.
Annals of hematology 2005;84(2):118-21.
2004: Simon Gibbs; Kirsten E Herbert; Christopher McCormack; John F Seymour; H Miles Prince
Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sézary syndrome.
European journal of haematology 2004;73(6):447-9.
2004: Constantine S Tam; Max M Wolf; E Henry Januszewicz; Andrew P Grigg; H Miles Prince; David Westerman; John F Seymour
A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies.
Cancer 2004;101(9):2042-9.
2004: Constantine S Tam; J Galanos; John F Seymour; A G Pitman; R J Stark; H Miles Prince
Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies.
American journal of hematology 2004;77(1):72-6.
2004: K E Herbert; A Spencer; A Grigg; Gail Ryan; Christopher McCormack; H Miles Prince
Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation.
Bone marrow transplantation 2004;34(6):521-5.
2004: H Miles Prince; Paul J Simmons; Genevieve A Whitty; Dominic P Wall; Lesley Barber; Guy C Toner; John F Seymour; Gary Richardson; Robert Mrongovius; David N Haylock
Improved haematopoietic recovery following transplantation with ex vivo-expanded mobilized blood cells.
British journal of haematology 2004;126(4):536-45.
2004: Susan J Morgan; John F Seymour; H Miles Prince; David Westerman; Max M Wolf
Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3572-5.
2004: Constantine S Tam; Max M Wolf; E Henry Januszewicz; H Miles Prince; David Westerman; John F Seymour
Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
Cancer 2004;100(10):2181-9.
2004: S J Morgan; John F Seymour; Andrew Grigg; Jane P Matthews; H Miles Prince; Max M Wolf; E Henry Januszewicz
Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine.
Leukemia 2004;18(5):1034-8.
2004: Constantine S Tam; H Miles Prince; David Westerman; John F Seymour; Surender Juneja
Leukaemic subtype of marginal zone lymphoma: a presentation of three cases and literature review.
Leukemia & lymphoma 2004;45(4):705-10.
2004: Glen A Kennedy; Robert Blum; Christopher McCormack; H Miles Prince
Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases.
The Australasian journal of dermatology 2004;45(1):34-7.
2004: Linda Mileshkin; Robert Blum; John F Seymour; Andrew Patrikeos; Rodney J Hicks; H Miles Prince
A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma.
European journal of haematology 2004;72(1):32-7.
2003: Linda Mileshkin; H Miles Prince; John F Seymour; James J Biagi
Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide.
British journal of haematology 2003;123(4):747-8; author reply 748.
2003: H Miles Prince; Christopher McCormack; Gail Ryan; Rod O'Keefe; John F Seymour; Chris Baker
Management of the primary cutaneous lymphomas.
The Australasian journal of dermatology 2003;44(4):227-40; quiz 241-2.
2003: G A Kennedy; John F Seymour; M Wolf; H Januszewicz; J Davison; Christopher McCormack; Gail Ryan; H Miles Prince
Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
European journal of haematology 2003;71(4):250-6.
2003: Susan J Morgan; H Miles Prince; David Westerman; Christopher McCormack; Ian Glaspole
Clonal T-helper lymphocytes and elevated IL-5 levels in episodic angioedema and eosinophilia (Gleich's syndrome).
Leukemia & lymphoma 2003;44(9):1623-5.
2003: J N Machatschek; David Westerman; H Miles Prince; John F Seymour
A case of clinical indolent natural killer cell lineage large granular lymphocytic leukemia in a patient with rheumatoid arthritis.
Leukemia & lymphoma 2003;44(7):1223-7.
2003: Linda Mileshkin; James J Biagi; Paul Mitchell; Craig Underhill; Andrew Grigg; Richard Bell; Joe McKendrick; Peter Briggs; John F Seymour; Kate Lillie; Jennifer G Smith; Jerome B Zeldis; H Miles Prince
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.
Blood 2003;102(1):69-77.
2003: Lee Mei Yap; Robert Blum; Peter Foley; Christopher McCormack; Hugh Turner; John F Seymour; H Miles Prince
Clinical study of primary cutaneous B-cell lymphoma using both the European Organization for Research and Treatment of Cancer and World Health Organization classifications.
The Australasian journal of dermatology 2003;44(2):110-5.
2003: Kirsten E Herbert; H Miles Prince; David A Westerman
Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab.
Blood 2003;101(4):1654.
2003: H Miles Prince; Lee Mei Yap; Robert Blum; Christopher McCormack
Primary cutaneous B-cell lymphomas.
Clinical and experimental dermatology 2003;28(1):8-12.
2002: S L Chua; John F Seymour; J Streater; Max M Wolf; E Henry Januszewicz; H Miles Prince
Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.
Leukemia & lymphoma 2002;43(9):1783-8.
2002: Robert Blum; H Miles Prince; Rodney J Hicks; Andrew Patrikeos; John Seymour
Discordant response to chemotherapy detected by PET scanning: unveiling of a second primary cancer.
American journal of clinical oncology 2002;25(4):368-70.
2002: H Miles Prince; Rod O'Keefe; Christopher McCormack; Gail Ryan; Hugh Turner; Paul Waring; Chris Baker
Cutaneous lymphomas: which pathological classification?
Pathology 2002;34(1):36-45.
2002: H Miles Prince; D Wall; Danny Rischin; Guy C Toner; John F Seymour; D Blakey; David N Haylock; P Simmons; Max Wolf; E Henry Januszewicz; David Westerman; Gary Richardson; J Scarlett; P Briggs
CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy.
Cytotherapy 2002;4(2):147-55.
2002: H Miles Prince; John Bashford; D Wall; Danny Rischin; N Parker; Guy C Toner; John F Seymour; D Blakey; David N Haylock; P Simmons; P Francis; Max Wolf; E Henry Januszewicz; Gary Richardson; J Scarlett; P Briggs
Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy.
Cytotherapy 2002;4(2):137-45.
2001: James J Biagi; Linda Mileshkin; A P Grigg; D W Westerman; H Miles Prince
Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation.
Bone marrow transplantation 2001;28(12):1145-50.
2001: A J Dowling; H Miles Prince; A Wirth; M Wolf; E Henry Januszewicz; Surender Juneja; John F Seymour; P Gates; J G Smith
High-dose therapy and autologous transplantation for lymphoma: The Peter MacCallum Cancer Institute experience.
Internal medicine journal 2001;31(5):279-89.
2001: H Miles Prince; Danny Rischin; M Quinn; D Allen; R Planner; D Neesham; P Gates; J Davison
Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
Gynecologic oncology 2001;81(2):216-24.
2001: H Miles Prince; Christopher McCormack; Gail Ryan; Chris Baker; H Rotstein; J Davison; R Yocum
Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials.
The Australasian journal of dermatology 2001;42(2):91-7.
2001: Linda Mileshkin; H Miles Prince; Danny Rischin; A Zimet
Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature.
Bone marrow transplantation 2001;27(5):559-63.
2000: H Miles Prince; Danny Rischin; Guy C Toner; John F Seymour; D Blakey; P Gates; S Eerhard; Peter Chapple; M Quinn; M Brettell; Surender Juneja; Max Wolf; E Henry Januszewicz; Gary Richardson; J Scarlett; P Briggs
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Bone marrow transplantation 2000;26(9):955-61.
2000: H Miles Prince; Guy C Toner; John F Seymour; D Blakey; P Gates; S Eerhard; Peter Chapple; D Wall; M Quinn; Surender Juneja; Max Wolf; E Henry Januszewicz; Gary Richardson; J Scarlett; P Briggs; M Brettell; Danny Rischin
Docetaxel effectively mobilizes peripheral blood CD34+ cells.
Bone marrow transplantation 2000;26(5):483-7.
2000: S L Chua; John F Seymour; H Miles Prince
Deafness from eighth cranial nerve involvement in a patient with large-cell transformation of mycosis fungoides.
European journal of haematology 2000;64(5):340-3.
2000: Surender Juneja; L Trute; David Westerman; Deon J Venter; John F Seymour; H Miles Prince
Paraffin section immunotyping of leukaemias.
British journal of haematology 2000;109(2):267-71.
2000: Peter Chapple; H Miles Prince; D Wall; R Filshie; D Haylock; M Quinn; M Bretell; Deon J Venter
Comparison of three methods of CD34+ cell enumeration in peripheral blood: dual-platform ISHAGE protocol versus single-platform, versus microvolume fluorimetry.
Cytotherapy 2000;2(5):371-6.
1999: J F Seymour; Surender Juneja; L J Campbell; P H Ellims; E H Estey; H Miles Prince
Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy.
Leukemia 1999;13(11):1735-40.
1999: A H Strickland; C Seymour; H Miles Prince; M Wolf; Surender Juneja; E Henry Januszewicz
Fludarabine and high dose cytarabine (FLA): a well tolerated salvage regimen in acute myeloid leukaemia.
Australian and New Zealand journal of medicine 1999;29(4):556-8.
1999: Surender Juneja; D Carney; D Ellis; E Henry Januszewicz; M Wolf; H Miles Prince
Hodgkin's disease type Richter's syndrome in chronic lymphocytic leukemia.
Leukemia 1999;13(5):826-7.
1999: H Miles Prince; Michael J Millward; Danny Rischin; D Blakey; P Francis; P Gates; Peter Chapple; M Quinn; Surender Juneja; Max Wolf; E Henry Januszewicz; John F Seymour; M Brettell; A Strickland; John Zalcberg; Gary Richardson; J Scarlett; P Briggs; Guy C Toner
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):479-81.
1999: H Miles Prince; J Gardyn; Michael J Millward; Danny Rischin; P Francis; P Gates; Peter Chapple; M Quinn; Surender Juneja; Max Wolf; E Henry Januszewicz; Gary Richardson; J Scarlett; P Briggs; M Brettell; Guy C Toner
Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer.
Bone marrow transplantation 1999;23(5):427-35.
1999: R Wilke; M Brettell; H Miles Prince; Max Wolf; R McKenna; E Serpell; M Molloy; H Stevens; M Quinn; P Gates; Peter Chapple
Comparison of COBE Spectra software version 4.7 PBSC and version 6.0 auto PBSC program.
Journal of clinical apheresis 1999;14(1):26-30.
1998: H Miles Prince
Gene transfer: a review of methods and applications.
Pathology 1998;30(4):335-47.
1998: Peter Chapple; H Miles Prince; M Quinn; Ivan Bertoncello; Surender Juneja; Max Wolf; H Januszewicz; M Brettell; J Gardyn; C Seymour; Deon J Venter
Peripheral blood CD34+ cell count reliably predicts autograft yield.
Bone marrow transplantation 1998;22(2):125-30.
1998: A J Martinow; K Yuen; IA Cooper; Jane P Matthews; Surender Juneja; Max Wolf; H Januszewicz; H Miles Prince
Prognostic markers of disease activity in Hodgkin's disease.
Leukemia & lymphoma 1998;29(3-4):383-9.